keyword
MENU ▼
Read by QxMD icon Read
search

Non-alcoholic steatohepatitis

keyword
https://www.readbyqxmd.com/read/28928235/testosterone-protects-high-fat-low-carbohydrate-diet-induced-non-alcoholic-fatty-liver-disease-in-castrated-male-rats-mainly-via-modulating-er-stress
#1
Yue Jia, Jennifer Kuang Yee, Christina Wang, Liana Nikolaenko, Maruja Diaz-Arjonilla, Joshua N Cohen, Samuel W French, Peter Y Liu, YanHe Lue, Wai-Nang Paul Lee, Ronald S Swerdloff
We previously showed that testosterone (T) deficiency enhanced high-fat diet (HFD) induced hepatic steatosis in rats that was independent of insulin resistance, and that T replacement reduced hepatic macrovesicular fat accumulation and inflammation. The present report explores the mechanism of T-protective effects on HFD-induced steatohepatitis. Adult male rats were randomized into four treatment groups for 15 weeks (intact rats on regular chow diet or HFD, and castrated rats on HFD with/without T replacement)...
September 19, 2017: American Journal of Physiology. Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28924123/the-improvement-of-the-hepatic-histological-findings-in-a-patient-with-non-alcoholic-steatohepatitis-with-type-2-diabetes-after-the-administration-of-the-sodium-glucose-cotransporter-2-inhibitor-ipragliflozin
#2
Akihiko Takeda, Aya Irahara, Atsuko Nakano, Emi Takata, Yuko Koketsu, Kunie Kimata, Eri Senda, Hajime Yamada, Kazuhito Ichikawa, Takahiro Fujimori, Yoshio Sumida
The patient was a 67-year-old woman with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The administration of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, ipragliflozin improved her liver dysfunction clinically and histologically. The serum alanine aminotransferase (ALT) and ferritin levels decreased to normal limits after treatment for four months. Type IV collagen and hyaluronic acid, both of which were serum fibrotic markers, decreased after treatment. Ultrasonography and computed tomography showed a decrease in the fat deposits in her liver...
September 15, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28922438/endocan-serum-levels-in-patients-with-non-alcoholic-fatty-liver-disease-with-or-without-type-2-diabetes-mellitus-a-pilot-study
#3
Marcello Dallio, Mario Masarone, Giuseppe Gerardo Caprio, Rosa Di Sarno, Concetta Tuccillo, Ferdinando Carlo Sasso, Marcello Persico, Carmela Loguercio, Alessandro Federico
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is emerging as an independent cardiovascular risk factor. Recently, Endocan has been studied as an early marker of endothelial dysfunction. Our aim was to evaluate Endocan serum levels in patients with NAFLD with or without type 2 diabetes mellitus. METHOD: We enrolled 56 patients: 19 with NAFLD and 37 with type 2 diabetes mellitus with or without NAFLD, and compared them to 25 healthy controls. Endocan serum level was measured by using the ELISA EndoMark assay...
September 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/28921469/microbial-factors-in-inflammatory-diseases-and-cancers
#4
Hong Sheng Ong, Howard Chi Ho Yim
The intestinal microbes form a symbiotic relationship with their human host to harvest energy for themselves and their host and to shape the immune system of their host. However, alteration of this relationship, which is named as a dysbiosis, has been associated with the development of different inflammatory diseases and cancers. It is found that metabolites, cellular components, and virulence factors derived from the gut microbiota interact with the host locally or systemically to modulate the dysbiosis and the development of these diseases...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28918389/glucagon-like-peptide-1-receptor-agonists-for-the-management-of-obesity-and-non-alcoholic-fatty-liver-disease-a-novel-therapeutic-option
#5
REVIEW
Gauri Dhir, Kenneth Cusi
Obesity is a major risk factor for the development of type 2 diabetes mellitus (T2DM), and is associated with a cluster of metabolic factors that lead to poor cardiovascular outcomes. In non-alcoholic fatty liver disease (NAFLD), liver fat (triglyceride) accumulation closely mirrors adipose tissue dysfunction and insulin resistance in obesity and T2DM. It is now recognized as the most common chronic liver disease in Westernized societies, often progressing to more severe forms of the disease such as nonalcoholic steatohepatitis (NASH), or cirrhosis and hepatocellular carcinoma...
September 15, 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/28906453/vitamin-d-supplementation-and-non-alcoholic-fatty-liver-disease-present-and-future
#6
REVIEW
Ilaria Barchetta, Flavia Agata Cimini, Maria Gisella Cavallo
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disease throughout the Western world and is recognized as the main cause of cryptogenic cirrhosis; however, the identification of an effective therapy for NAFLD is still a major challenge. Vitamin D deficiency is a wide-spread condition which reaches epidemic proportions in industrialized countries, mainly in relation to current lifestyle and limited dietary sources. Epidemiological studies point towards an association between hypovitaminosis D and the presence of NAFLD and steatohepatitis (NASH), independently of confounders such as obesity and insulin resistance...
September 14, 2017: Nutrients
https://www.readbyqxmd.com/read/28900305/berberine-ameliorates-fatty-acid-induced-oxidative-stress-in-human-hepatoma-cells
#7
Yixuan Sun, Xinlu Yuan, Feifei Zhang, Yamei Han, Xinxia Chang, Xi Xu, Yu Li, Xin Gao
Oxidative stress is thought to be critical for the pathogenesis of hepatic steatosis and its progress to non-alcoholic steatohepatitis. Berberine (BBR) can improve hepatic steatosis. In this study, we investigated the role of BBR in ameliorating oxidative stress. Lipid accumulation was measured in the livers of C57BL/6 mice fed a high fat diet (HFD) or a normal diet for 8 weeks, then either received BBR or vehicle for the study duration. Nrf2 distribution was detected in male Sprague-Dawley rats' livers in vivo and in Huh7 cells in vitro...
September 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28899715/the-relationship-between-25-hydroxyvitamin-d-concentration-and-liver-enzymes-in-overweight-or-obese-adults-cross-sectional-and-interventional-outcomes
#8
Negar Naderpoor, Aya Mousa, Maximilian de Courten, Robert Scragg, Barbora de Courten
Vitamin D deficiency is prevalent in individuals with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis. However, there is limited and inconsistent data on the effect of vitamin D supplementation on liver function. Hepatic enzymes have been used as surrogate markers for NAFLD and have been associated with metabolic syndrome. We examined the relationships between 25-hydroxyvitamin D (25(OH)D) and γ-glutamyl transferase (GGT), alanine aminotransferase (ALT), alkaline phosphatase (ALP) in 120 drug-naïve individuals with no history of liver disease...
September 9, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28898507/growth-differentiation-factor-15-predicts-advanced-fibrosis-in-biopsy-proven-non-alcoholic-fatty-liver-disease
#9
Bo Kyung Koo, Sung Hee Um, Dong Soo Seo, Sae Kyung Joo, Jeong Mo Bae, Jeong Hwan Park, Mee Soo Chang, Jung Ho Kim, Jieun Lee, Won-Il Jeong, Won Kim
BACKGROUND & AIMS: We explored whether growth differentiation factor 15 (GDF15) affects the histological severity of non-alcoholic fatty liver disease (NAFLD) independent of insulin resistance. METHODS: In a biopsy-proven NAFLD cohort, we measured serum GDF15 levels using enzyme-linked immunosorbent assays. RESULTS: Among 190 subjects (mean age, 53±14 years; men, 52.1%), 72 (men, 65.3%) and 78 (men, 44.9%) were diagnosed with biopsy-proven non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), respectively...
September 12, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28895929/effects-of-oral-administration-of-silymarin-in-a-juvenile-murine-model-of-non-alcoholic-steatohepatitis
#10
Veronica Marin, Silvia Gazzin, Sabrina E Gambaro, Matteo Dal Ben, Sonia Calligaris, Monica Anese, Alan Raseni, Claudio Avellini, Pablo J Giraudi, Claudio Tiribelli, Natalia Rosso
The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in adolescents is challenging the global care system. No therapeutic strategies have been defined so far, and changes in the lifestyle remain the only alternative. In this study, we assessed the protective effects of silymarin in a juvenile non-alcoholic steatohepatitis (NASH) model and the in vitro effects on fat-laden human hepatocytes. C57Bl/6 mice were exposed to HFHC diet immediately after weaning. After eight weeks, animals showed histological signs of NASH...
September 12, 2017: Nutrients
https://www.readbyqxmd.com/read/28895242/hepatocellular-carcinoma-in-a-mouse-model-fed-a-choline-deficient-l-amino-acid-defined-high-fat-diet
#11
Ayae Ikawa-Yoshida, Saori Matsuo, Atsuhiko Kato, Yusuke Ohmori, Atsuko Higashida, Eiji Kaneko, Masahiko Matsumoto
Hepatocellular carcinoma (HCC) is a common cancer worldwide and represents the outcome of the natural history of chronic liver disease. The growing rates of HCC may be partially attributable to increased numbers of people with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). However, details of the liver-specific molecular mechanisms responsible for the NAFLD-NASH-HCC progression remain unclear, and mouse models that can be used to explore the exact factors that influence the progression of NAFLD/NASH to the more chronic stages of liver disease and subsequent HCC are not yet fully established...
September 12, 2017: International Journal of Experimental Pathology
https://www.readbyqxmd.com/read/28880885/markers-of-intestinal-permeability-are-already-altered-in-early-stages-of-non-alcoholic-fatty-liver-disease-studies-in-children
#12
Anika Nier, Anna Janina Engstler, Ina Barbara Maier, Ina Bergheim
BACKGROUND & AIMS: Recent studies have shown that patients with manifest non-alcoholic fatty liver disease (NAFLD), e.g. steatosis grade 3 or steatohepatitis with or without beginning fibrosis frequently show altered fecal microbiota composition and elevated bacterial endotoxin levels. However, if these alterations are signs of a progressing disease or are already found in initial disease stages has not yet been clarified. METHODS: Twenty children with simple steatosis (grade 1) diagnosed by ultrasound and 29 normal weight healthy control children (age <10 years) were included in the study (mean age 7...
2017: PloS One
https://www.readbyqxmd.com/read/28880451/editorial-treatments-for-non-alcoholic-steatohepatitis-still-a-long-way-to-go
#13
EDITORIAL
N Rosso, C Tiribelli
No abstract text is available yet for this article.
October 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28878826/analysis-of-factors-influencing-glucose-tolerance-in-japanese-patients-with-non-alcoholic-fatty-liver-disease
#14
Satoko Ohmi, Masafumi Ono, Hiroshi Takata, Seiki Hirano, Shogo Funakoshi, Yuichi Nishi, Kumiko Yoshimura, Eri Amano, Yoshio Terada, Toshiji Saibara, Shimpei Fujimoto
BACKGROUND: While the association of the prevalence of non-alcoholic fatty liver disease (NAFLD) with impaired glucose metabolism has been reported, the factors influencing glucose tolerance in NAFLD remain to be clarified. METHODS: Glucose tolerance of 131 Japanese patients diagnosed as NAFLD by histological findings of liver biopsy specimen was examined using 75 g-OGTT. According to Matteoni's classification, patients were divided to 4 groups [M1 ~ 4, M1, 2: non-alcoholic fatty liver (NAFL); and M3, 4: non-alcoholic steatohepatitis (NASH)]...
2017: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/28875438/non-invasive-evaluation-of-nafld-with-indocyanine-green-clearance-test-a-preliminary-study-in-morbidly-obese-patients-undergoing-bariatric-surgery
#15
Pierre Eric Danin, Rodolphe Anty, Stephanie Patouraux, Marc Raucoules-Aimé, Jean Gugenheim, Albert Tran, Philippe Gual, Antonio Iannelli
BACKGROUND: Overweight and obesity dramatically increased in the last years. Hepatic complication of obesity, integrated in the term of non-alcoholic fatty liver disease (NAFLD), is a spectrum of abnormality ranging from steatosis to non-alcoholic steatohepatitis (NASH), potentially leading to cirrhosis. Liver biopsy remains the gold standard to evaluate the stage of NAFLD; however, the procedure is invasive. The indocyanine green (ICG) clearance test is performed since years to assess hepatic function before partial hepatectomy, or after liver transplantation...
September 5, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28874844/serum-monounsaturated-triacylglycerol-predicts-steatohepatitis-in-patients-with-non-alcoholic-fatty-liver-disease-and-chronic-hepatitis-b
#16
Rui-Xu Yang, Chun-Xiu Hu, Wan-Lu Sun, Qin Pan, Feng Shen, Zhen Yang, Qing Su, Guo-Wang Xu, Jian-Gao Fan
Chronic liver disease is associated with lipid metabolic disruption. We carried out a study to determine serum lipidomic features of patients with non-alcoholic fatty liver disease (NAFLD) and active chronic hepatitis B (CHB) and explored the biomarkers for non-alcoholic steatohepatitis (NASH). Serum lipidomic profiles of healthy controls (n = 23) and of biopsy-proven NAFLD (n = 42), CHB with NAFLD (n = 22) and without NAFLD (n = 17) were analyzed by ultra-performance liquid chromatography-tandem mass spectrometry...
September 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28874443/amelioration-of-diet-induced-steatohepatitis-in-mice-following-combined-therapy-with-aso-fsp27-and-fenofibrate
#17
Ananthi Rajamoorthi, Noemi Arias, Jeannine Basta, Richard G Lee, Ángel Baldán
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. NAFLD progresses from benign steatosis to steatohepatitis (NASH) to cirrhosis, and is linked to hepatocellular carcinoma. No targeted treatment is currently approved for NAFLD/NASH. We showed that fat-specific protein 27 (FSP27), a lipid droplet-associated protein that controls triglyceride turnover in the hepatocyte, is required for fasting- and diet-induced triglyceride accumulation in the liver. However, silencing Fsp27 with antisense oligonucleotides (ASOs) did not improve hepatosteatosis in genetic nor nutritional mouse models of obesity...
September 5, 2017: Journal of Lipid Research
https://www.readbyqxmd.com/read/28874313/new-therapeutic-perspectives-in-non-alcoholic-steatohepatitis
#18
Javier Ampuero, Yolanda Sánchez-Torrijos, Virginia Aguilera, Francisco Bellido, Manuel Romero-Gómez
Management of non-alcoholic steatohepatitis is focused on restitution of metabolic derangement, weight loss and drugs able to improve steatosis, ballooning and fibrosis. Life-style interventions based on Mediterranean diet and increasing physical activity are the first line therapy. In patients with unsuccessful life-style intervention several drugs are under development: agonist PPAR, agonist GLP-1R and agonist FXR together with drugs focussing on inflammation, ballooning, apoptosis and fibrosis. Bariatric surgery or advanced endoscopy are reserved for morbid obese without response to life-style intervention and weighting loss drugs...
September 2, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28873429/cd18-deficiency-improves-liver-injury-in-the-mcd-model-of-steatohepatitis
#19
Andrew A Pierce, Caroline C Duwaerts, Kevin Siao, Aras N Mattis, Amanda Goodsell, Jody L Baron, Jacquelyn J Maher
Neutrophils and macrophages are important constituents of the hepatic inflammatory infiltrate in non-alcoholic steatohepatitis. These innate immune cells express CD18, an adhesion molecule that facilitates leukocyte activation. In the context of fatty liver, activation of infiltrated leukocytes is believed to enhance hepatocellular injury. The objective of this study was to determine the degree to which activated innate immune cells promote steatohepatitis by comparing hepatic outcomes in wild-type and CD18-mutant mice fed a methionine-choline-deficient (MCD) diet...
2017: PloS One
https://www.readbyqxmd.com/read/28868179/fatty-liver-without-a-large-belly-magnified-review-of-non-alcoholic-fatty-liver-disease-in-non-obese-patients
#20
REVIEW
Mohamad H Yousef, Alhareth Al Juboori, Abdulmajeed A Albarrak, Jamal A Ibdah, Veysel Tahan
Nonalcoholic fatty liver disease (NAFLD) is well described as a common cause of chronic liver disease, mostly in the obese population. It refers to a spectrum of chronic liver disease that starts with simple steatosis than progresses to nonalcoholic steatohepatitis and cirrhosis in patients without significant alcohol consumption. NAFLD in the non-obese population has been increasingly reported and studied recently. The pathogenesis of nonobese NAFLD is poorly understood and is related to genetic predisposition, most notably patatin-like phospholipase domain-containing 33 G allele polymorphism that leads to intrahepatic triglyceride accumulation and insulin resistance...
August 15, 2017: World Journal of Gastrointestinal Pathophysiology
keyword
keyword
12440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"